NCT04322955 - CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2020

Primary Completion Date

May 31, 2027

Study Completion Date

February 29, 2028

Conditions

Kidney CancerRenal Cell Carcinoma

Interventions

DRUG

Cabozantinib

2 x 20 mg capsules taken orally daily

DRUG

Nivolumab

480mg IV on first day of each 28-day cycle

PROCEDURE

Cytoreductive nephrectomy

Surgery removing as much tumor tissue as possible, possibly including surrounding tissues.

Trial Locations (4)

RECRUITING

Columbia University Irving Medical Center, New York

RECRUITING

Ohio State University Wexner Medical Center, Columbus

RECRUITING

Cleveland Clinic, Cleveland

RECRUITING

The Rutgers Cancer Institute of New Jersey, New Brunswick